血液蛋白质组学:寻找最合适的肿瘤标志物
  • 肿瘤早期诊断的概念,助推了精准诊断,肿瘤的早期诊断可让患者获益更多;
  • 亲和蛋白质组学可准确测量血清中的诊断信息,这些可操作的信息可用以指导肿瘤的精准和循证医学治疗(预测性标志物)以及精准预测预后(预后性标志物);
  • 从单一标志物的应用转变为多个含可评估信息的标志物的联合应用,称之为识别特征,可大幅提高诊断的准确率;
  • 本文综述了血液蛋白质组学(液体活检),阐述了蛋白质生物标志物识别特征的临床应用。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer

精准诊断:蛋白质生物标志物识别特征的临床应用

10.1038/nrc.2016.153

2017-02-03, Opinion

Abstract & Authors:展开

Abstract:收起
Interest in precision diagnostics has been fuelled by the concept that early detection of cancer would benefit patients; that is, if detected early, more tumours should be resectable and treatment more efficacious. Serum contains massive amounts of potentially diagnostic information, and affinity proteomics has risen as an accurate approach to decipher this, to generate actionable information that should result in more precise and evidence-based options to manage cancer. To achieve this, we need to move from single to multiplex biomarkers, a so-called signature, that can provide significantly increased diagnostic accuracy. This Opinion article focuses on the progress being made in identifying protein biomarker signatures of clinical utility, using blood-based proteomics.

First Authors:
Carl A K Borrebaeck

Correspondence Authors:
Carl A K Borrebaeck

All Authors:
Carl A K Borrebaeck

评论